The Fertility Collision: When Treating Low Testosterone Destroys the Capacity to Reproduce

In 2024, American physicians wrote more than 11 million prescriptions for testosterone — a 50% surge from 7.3 million just five years earlier. The sharpest growth was in men under 45, where prescriptions increased fourfold. After the FDA removed its cardiovascular black-box warning in February 2025, a December 2025 advisory panel pushed further: remove the prostate cancer contraindication, expand eligibility, consider descheduling testosterone from Schedule III entirely.

In the same year, a research team published a paper with a title that should appear on every prescription label: "Testosterone Is a Contraceptive and Should Not Be Used in Men Who Desire Fertility."

These two facts coexist. One system accelerates access to a hormone. Another system documents that the same hormone — at the same doses, through the same mechanisms — suppresses sperm production so reliably that it is being developed as the first hormonal male contraceptive in history. In February 2026, Contraline executed a global license for the NES/T gel and began planning the first-ever Phase III trial of a hormonal male contraceptive.

The collision is not hypothetical. It is happening in every clinic that prescribes testosterone without asking whether the patient wants children.

What Testosterone Does to Sperm

The mechanism is straightforward and absolute. Exogenous testosterone suppresses GnRH from the hypothalamus, which suppresses LH and FSH from the pituitary. Without LH, the Leydig cells stop producing intratesticular testosterone — the local concentration that spermatogenesis requires (50-100× serum levels). Without FSH, Sertoli cells lose the signal to support sperm maturation. The result: even as blood testosterone normalizes, the testes shut down.

But the rate at which this happens, and whether it's reversible, depends almost entirely on the formulation — a fact that almost no one communicates to patients.

The pattern is not subtle. The longer a formulation suppresses gonadotropins continuously, the more completely it shuts down sperm production. Weekly intramuscular injections hold the HPG axis in sustained suppression — 65% azoospermia. Pellets, which release over months, hit ~40%. But short-acting formulations allow gonadotropin pulsatility to recover between doses: oral testosterone (~5 hour half-life) drops to ~5% azoospermia. Intranasal, with its ~1 hour half-life and three-times-daily dosing, barely suppresses spermatogenesis at all — 1.7%.

This gradient is the most important finding in reproductive endocrinology that almost no patient hears. And notice the void at the center: transdermal gel and patches — the most commonly prescribed TRT formulation in America — have no controlled semen data whatsoever. The formulation that most men receive has never been studied for the outcome that matters most to men of reproductive age.

The Contraception Irony

The WHO ran male hormonal contraception trials in 1990 and 1996 using the same injectable testosterone prescribed for hypogonadism. The results proved it works: 98% achieved azoospermia or severe oligospermia (<3 million/mL). The 2016 WHO trial combined testosterone with a progestin — then was terminated early for mood and depression side effects. The rates were comparable to those documented in women's hormonal contraceptives. The double standard was noted but not resolved.

Now, Contraline's NES/T gel combines nestorone (a synthetic progestin) with testosterone. The Phase IIb trial in 462 couples showed 86% suppression to ≤1 million/mL and 78% azoospermia. In February 2026, Contraline executed a global exclusive license from the Population Council and began planning the Phase III trial — the first Phase III of a hormonal male contraceptive in the history of medicine.

The 5% of men who never achieve azoospermia even on supraphysiologic testosterone remain unexplained. Their pituitary glands resist suppression — higher baseline LH, less gonadotropin decline. The genetic determinants are unidentified. This is simultaneously the failure case for contraception research and the success case for fertility preservation. No one studies them.

There is also a stark ethnic variability: WHO data showed Asian men achieved 91% azoospermia versus 60% in non-Asian men. The UGT2B17 deletion polymorphism (prevalent in East Asian populations) partially explains this — altered testosterone metabolism means different suppressive thresholds. This pharmacogenomic dimension is entirely absent from clinical TRT counseling.

The Prescribing Surge Nobody Counsels

Between 2018 and 2022, testosterone prescriptions rose 120% in men aged 24 and younger, 86% in ages 25-34, and 58% in ages 35-44 — precisely the demographic most likely to want children in the future. More than 325 new testosterone clinics have opened since early 2024. Hims & Hers alone reported 2.4 million subscribers across health offerings in 2025, up 31%. In 2026, Hims launched Kyzatrex (oral testosterone undecanoate), compounded enclomiphene, and injectable testosterone on its platform — the full spectrum, delivered by mail.

The counseling infrastructure has not kept pace with the prescribing infrastructure.

The Dubin 2022 study deserves emphasis. Researchers posed as secret shoppers at seven DTC testosterone platforms, presenting as men with normal testosterone levels who explicitly stated they wanted to preserve fertility. Six of seven platforms — 85.7% — offered testosterone anyway. This is not a systemic failure at the edges. It is the system working exactly as designed: to sell testosterone.

The Treatment Spectrum That Exists but Isn't Used

The tragedy is not that we lack options. It is that the options exist and sit unused while the bluntest instrument dominates.

The Hochu 2025 review in Translational Andrology and Urology laid this spectrum out clearly: enclomiphene achieved a 63.5% composite efficacy endpoint versus 24.7% for testosterone gel versus 5.8% for placebo — while preserving fertility entirely. The Hohl 2025 meta-analysis of 10 RCTs (819 patients) found SERMs increased testosterone by 274 ng/dL — statistically equivalent to topical testosterone — while significantly improving sperm concentration compared to gel.

The Baylor hCG/FSH protocol (Stocks 2024-2025) demonstrated that even men already on TRT could recover: 74% improved sperm production with concurrent hCG plus FSH, and 64.9% of azoospermic men recovered detectable sperm. The conversion doesn't require a washout period — Kavoussi 2022 showed that switching from long-acting TRT directly to intranasal testosterone restored spermatogenesis in 100% of men within three months.

And then there is the finding that reframes everything: Gregorič et al. (Diabetes Obesity and Metabolism, 2025) published the first head-to-head RCT of semaglutide versus TRT. Sperm concentration increased 16.7% with semaglutide while falling 60.6% with TRT (p=0.039). A GLP-1 receptor agonist didn't just preserve fertility — it improved it, while simultaneously raising testosterone through HPG axis restoration. The BSSM's 2026 consensus statement formally endorsed enclomiphene as "a promising oral therapy" — the first major society endorsement.

The Sperm Count Debate: What Is Actually Declining?

The backdrop to this clinical story is a global argument about whether sperm counts are falling. The answer matters because it determines whether iatrogenic harm (TRT-induced) is adding to an existing crisis or is an independent problem.

Levine et al. (Human Reproduction Update, 2023) updated their landmark 2017 meta-regression: sperm concentration declined 51.6% from 1973 to 2018, with the rate of decline accelerating after 2000. The 2023 update extended to South America, Asia, and Africa. This has driven the narrative of a global fertility crisis, reaching the New York Times, Congress, and Shanna Swan's Count Down.

But in January 2025, Lundy et al. (Fertility and Sterility) — from the Cleveland Clinic — published a systematic review and meta-analysis of 58 articles covering 11,787 American men from 1970 to 2018. Their finding: no significant decline in sperm concentration among fertile American men or the general US population without known infertility. Total sperm count actually increased by 2.9 million per year.

These are not contradictory findings — they are measuring different populations with different selection criteria. Levine's "unselected by fertility" cohorts include men presenting to clinics for any reason, capturing the sick, the obese, the medicated. Lundy's focus on fertile men and general population without known infertility selects for healthier baselines. The global decline may be real and driven by the same metabolic and environmental factors that drive secondary hypogonadism — obesity, EDCs, microplastics — while the healthy baseline remains stable.

What both groups agree on: the iatrogenic problem — TRT-induced infertility — is a separate issue from any environmental decline, and it is entirely preventable.

The Environmental Backdrop

The environmental threat to male fertility is real, even if its population-level impact remains debated. The data has become difficult to ignore.

Microplastics have been detected in 100% of human testes tested (Hu et al., Toxicological Sciences 2024, n=23), at a mean concentration of 328.44 μg/g — three times higher than dogs, and second only to the brain in human tissue concentration. Twelve polymer types were identified, with polyethylene dominant. In semen, 75.6% of samples contained microplastics (Toxics 2025), with PTFE — itself a fluoropolymer in the PFAS family — the most prevalent at 41%.

The ESHRE 2025 meta-analysis, presented at the European Society of Human Reproduction and Embryology annual meeting, quantified the impact: testicular samples positive for microplastics showed sperm concentrations of 12 million/mL versus 26 million/mL in negative samples. PFAS compounds in seminal fluid independently reduced progressive motility and increased DNA fragmentation, with epigenetic alterations showing transgenerational potential.

The mechanism hierarchy is now established in animal models: oxidative stress initiates the cascade, driving inflammation and mitochondrial dysfunction, which impairs Leydig cell steroidogenesis (via LHR/cAMP/PKA/StAR downregulation) and disrupts the blood-testis barrier. The testes are uniquely vulnerable — lipophilic polymers concentrate there because the testicular lipid content and high blood flow create a sink.

But microplastic exposure is not something a physician can prescribe against. The iatrogenic fertility collision — the one caused by testosterone prescriptions — is preventable today, with existing tools, using no new science.

The Gap

Fewer than 2% of men receive a baseline semen analysis before starting TRT. Twenty consecutive men presenting with TRT-induced azoospermia had received zero fertility counseling. Sperm banking costs $500-1,000 upfront and has no culture of routine use. And the AUA still formally states that all exogenous testosterone is contraindicated in men desiring fertility — yet does not require the prescribing infrastructure to enforce this.

The standard of care says one thing. The market does another. And the patients — mostly young, mostly underinformed, mostly driven to DTC platforms by symptoms that feel urgent — are caught between the two.

Every one of these interventions uses existing science and existing tools. None requires a new drug, a new trial, or a new technology. The knowledge exists. The treatment spectrum exists. The gap is not in the evidence — it is in the space between evidence and practice, where commercial incentives flow faster than clinical caution.

A man starting testosterone in 2026 has more treatment options than at any point in history. He also has a higher chance of never being told that the prescription could end his ability to have children. Both things are true. The collision continues.